Literature DB >> 1442683

Fistulosphincterotomy in the endoscopic approach to biliary tract diseases.

S Recchia1, F Coppola, A Ferrari, D Righi, E Zanon, G Verme.   

Abstract

We report our experience with 49 patients who underwent fistulosphincterotomy (FS) after cannulation of the common bile duct (CBD) by standard approaches had failed, due to suspected CBD obstruction. Only 4% of our cases turned out to have no biliary obstruction at all. The morbidity rate was 16%, and the mortality rate was 2%. In our series, FS raised the success rate of CBD cannulation from 90% to 96%. Ninety-five percent of successful cannulations were followed by endoscopic treatment. There were no cases of perforation or hemorrhage, and no difference in the success rate between FS in flat papillas and FS in bulging papillas, thanks, perhaps, to the technique we used. Our findings would indicate that FS is a useful procedure involving additional but not prohibitive risks. Nonetheless, it should be used only when CBD obstruction is strongly suspected and standard methods are not successful.

Entities:  

Mesh:

Year:  1992        PMID: 1442683

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

Review 1.  Precut sphincterotomy: indications, pitfalls, and complications.

Authors:  C J Larkin; K Huibregtse
Journal:  Curr Gastroenterol Rep       Date:  2001-04

2.  Precut fistulotomy for difficult biliary cannulation: is it a risky preference in relation to the experience of an endoscopist?

Authors:  Tae Hoon Lee; Byoung Wook Bang; Sang-Heum Park; Seok Jeong; Don Haeng Lee; Sun-Joo Kim
Journal:  Dig Dis Sci       Date:  2010-11-17       Impact factor: 3.199

3.  Needle-knife fistulotomy vs double-guidewire technique in patients with repetitive unintentional pancreatic cannulations.

Authors:  Su Jin Kim; Dae Hwan Kang; Hyung Wook Kim; Cheol Woong Choi; Su Bum Park; Byeong Jun Song; Young Mi Hong
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.